Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colitis Clear all
Completed No phase listed Observational Results available

Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis

NCT02438410
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Disease, IBD
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort

NCT02503514
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohns Disease, Ulcerative Colitis, Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Not yet recruiting Phase 4 Interventional

Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis

NCT07502339
View directory record Official record
Conditions
UC - Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

NCT03298022
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-168
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Newport Beach, California • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT03167437
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vorinostat, Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

NCT00790933
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
31
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Not applicable Interventional Results available

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

NCT02413047
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions
Azathioprine, 6 mercaptopurine, Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated No phase listed Observational

Mirikizumab Real World Protocol

NCT06696014
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1Phase 2 Interventional

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

NCT00267306
View directory record Official record
Conditions
Severe Ulcerative Colitis
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
16 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 22, 2026, 8:40 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

NCT01810185
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Low dose naltrexone, Placebo
Drug
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 2 Interventional

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

NCT06764615
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Zasocitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Glen Burnie, Maryland • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 2Phase 3 Interventional

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

NCT00279435
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 22, 2026, 8:40 AM EDT
Active, not recruiting Phase 4 Interventional

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

NCT04835506
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

Fecal Transplant for Ulcerative Colitis

NCT03948919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal microbiota, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 22, 2026, 8:40 AM EDT
Enrolling by invitation Phase 4 Interventional

INSIGHT-IBD Pragmatic Study

NCT07686757
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
Mirikizumab, Anti-TNF agents, anti-integrin antibodies, IL-12, IL-23
Drug
Lead sponsor
Specialty Networks Research.
Network
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Sun City, Arizona • Glenview, Illinois • Gurnee, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational Results available

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT03801928
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Inflectra
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
San Diego, California • Hamden, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 3 Interventional

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

NCT00744016
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Granulated mesalamine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bristol, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting No phase listed Observational

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06398626
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 3 Interventional

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
56
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 4 Interventional

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

NCT02345733
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Ulcerative Colitis Diet, Antibiotic cocktail
Other · Drug
Lead sponsor
Prof. Arie Levine
Government
Eligibility
8 Years to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational

Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease

NCT02054533
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fecal Microbiota Transplantation in Pediatric Patients

NCT02108821
View directory record Official record
Conditions
Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 22 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

NCT02840721
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
PF-06480605
Drug
Lead sponsor
Telavant, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Aventura, Florida • North Miami Beach, Florida • Pembroke Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 22, 2026, 8:40 AM EDT